Heterogeneous distribution of K-ras mutations in primary colon carcinomas: implications for EGFR-directed therapy-Reference-Cited by-同舟云学术

Heterogeneous distribution of K-ras mutations in primary colon carcinomas: implications for EGFR-directed therapy

Published:2011-05-15 Issue:10 Volume:26 Page:1271-1277
ISSN:0179-1958
Container-title:International Journal of Colorectal Disease
language:en
Short-container-title:Int J Colorectal Dis

Author:

Oltedal Satu,Aasprong Ole Gunnar,Møller Jannicke H.,Kørner Hartwig,Gilje Bjørnar,Tjensvoll Kjersti,Birkemeyer Elke M.,Heikkilä Reino,Smaaland Rune,Nordgård Oddmund

Publisher

Springer Science and Business Media LLC

Subject

Gastroenterology

Link

http://link.springer.com/content/pdf/10.1007/s00384-011-1233-5.pdf

Reference35 articles.

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. CA Cancer J Clin 59:225–249

2. Jiang Y, Kimchi ET, Staveley-O’Carroll KF, Cheng H, Ajani JA (2009) Assessment of K-ras mutation: a step toward personalized medicine for patients with colorectal cancer. Cancer 115:3609–3617

3. Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, Hayes DF, McAllister PK, Morton RF, Schilsky RL (2009) American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 27:2091–2096

4. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26:1626–1634

5. Karapetis CS, Khambata-Ford S, Jonker DJ, O’Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, Zalcberg JR (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359:1757–1765

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A pH-responsive cetuximab-conjugated DMAKO-20 nano-delivery system for overcoming K-ras mutations and drug resistance in colorectal carcinoma;Acta Biomaterialia;2024-03

2. A Bio-Responsive Cetuximab-Conjugated Dmako-20 Nano-Delivery System for Overcoming The K-Ras Mutations And Drug Resistance In Colorectal Carcinoma;2023

3. The role of KRAS and NRAS mutation detection in determining the therapy strategy for colorectal cancer;Bulletin of the Medical Institute "REAVIZ" (REHABILITATION, DOCTOR AND HEALTH);2022-10-31

4. Targeting the “undruggable” RAS with biologics;Advances in Cancer Research;2022

5. Selective and noncovalent targeting of RAS mutants for inhibition and degradation;Nature Communications;2021-05-11